TherapeuticsMD (TXMD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD Announces Third Quarter 2015 Financial Results
November 4, 2015 4:05 PM ESTTopline phase 3 data anticipated in fourth quarter for TX-004HR to treat symptoms of VVA
Completed enrollment in phase 3 Replenish Trial for first potential FDA-approved bio-identical oral combination hormone therapy
Management to host conference call today at 4:30 p.m. EST
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its third quarter financial results for the period ended September 30, 2015.
Recent and Third Quarter Developments
Revenues, net for the... More